Clinical Trial Update: Study to Evaluate the Benefits for the Patient Associated With the Treatment of Plaque Psoriasis With Apremilast After Other Systemic Treatment in Conditions of Clinical Practice in Spain

View source ↗

Summary

A completed real-world study in Spain evaluating the benefits of apremilast for plaque psoriasis in patients who have received prior systemic therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Apremilast (apremilast)

Snippet

Sponsor: Amgen | Conditions: Psoriasis | Status: COMPLETED